U.S. participant joins ATHENA trial conducted by Anaconda Biomed
Anaconda Biomed, a medical technology company, has made a significant stride in the field of stroke treatment with the enrolment and treatment of the first U.S. patient in its ATHENA clinical trial. The trial is designed to evaluate the safety and effectiveness of Anaconda's proprietary ANA Funnel Catheter, a device designed for use during stent retriever-based thrombectomy to facilitate clot removal.
The ANA Funnel Catheter boasts the largest capture diameter currently available for neuroendovascular thrombectomy, a feature that restricts flow during retrieval, enables simultaneous aspiration, and reduces the risk of clot fragmentation at capture. This makes it particularly suitable for patients suffering from large vessel occlusion acute ischemic stroke.
Stroke is a serious concern worldwide, with one in four people over the age of 25 expected to have a stroke in their lifetime. About 87% of these cases are classified as ischemic events caused by emboli or thrombotic occlusions in the neurovasculature. Due to the aging of the population and the strong association between stroke risk and age, the number of people experiencing stroke is expected to rise significantly, with a 34% increase in events projected by 2035.
Globally, stroke ranks among the top three leading causes of death and the primary cause of serious long-term disability. The ATHENA IDE study, a global, randomized clinical trial, aims to address this issue by providing further evidence of the ANA Funnel Catheter's safety and effectiveness in treating large vessel occlusion acute ischemic stroke.
Anaconda received IDE approval from the U.S. Food and Drug Administration to evaluate the ANA Funnel Catheter in the ATHENA trial in September 2024. The company plans to complete enrollment in the study in the first half of 2026, with a total of 327 patients involved.
Feasibility studies conducted with the ANA Funnel Catheter have demonstrated high rates of reperfusion and first-pass success, along with a strong safety profile. These promising results bode well for the ATHENA IDE study, which will provide crucial insights into the device's performance in improving patient outcomes during stroke interventions.
For the most current and detailed updates on ATHENA or Anaconda Biomed’s study, it is recommended to consult official clinical trial registries such as ClinicalTrials.gov or Anaconda Biomed’s official communications. The ATHENA Clinical Trial, in particular, is a pivotal study evaluating the safety and effectiveness of Anaconda's proprietary ANA Funnel Catheter, with the results expected to contribute significantly to the advancement of stroke treatment.
The ANA Funnel Catheter, a device developed by Anaconda Biomed, a medical technology company, is primarily designed for use in the field of stroke treatment, particular for patients suffering from large vessel occlusion acute ischemic stroke. This trial aims to alleviate the global burden of stroke, as it ranks among the top three leading causes of death and the primary cause of serious long-term disability. The ATHENA trial, which is currently enrolling patients, will contribute to the advancement of stroke treatment and health-and-wellness by providing evidence on the safety and effectiveness of the ANA Funnel Catheter. In the realm of finance and investing, the success of this trial could potentially have significant implications for Anaconda Biomed's business and technology sector.
